Research keywords (3)：
glycobiology
, oncology
, urology
Research theme for competitive and other funds (18)：
2022 - 2025 男性性機能を改善させる再生医療の開発
2020 - 2023 Investigation of new therapeutic target of renal cell carcinoma resistant to a tyrosine kinase inhibitor by elucidating the drug tolerance by cancer metabolomics
2020 - 2023 難治性膀胱痛症候群の病態分類と重症度を評価可能する尿中バイオマーカーの確立
2018 - 2021 Development of approach to improve functional outcome after robot-assisted radical prostatectomy
2017 - 2020 Glycoconjugate biomarker of Prostate cancer
2017 - 2020 A novel immunotherapy for advanced renal cell carinoma by glycobiological interaction with natural killer cells
2016 - 2019 Primary aldosteronism: Establishment of tissue-sparing adrenalectomy according to the results of segmental adrenal venous sampling
2015 - 2018 Establish new QOL evaluation method to maintain QOL of testicular cancer patients with long-term prognosis
2014 - 2017 Ganglioside DSGb5 as a biomarker of prostate cancer
2014 - 2017 Establishment of standard treatment for Renal tumor patients using nomogram for Japanese
2014 - 2017 Development of a new molecular targeted therapy focused on lipid rafts for renal cell carcinoma
2013 - 2016 Ganglioside DSGb5 as a new biomarker for prostate cancer treatment
2009 - 2011 Dose a novel biomarker, RM2-Haptoglobin-beta, has the possibility to exceed PSA in predicting outcome of prostate cancer?
2008 - 2010 Functional role of haptoglobin-β chain defined by RM2 in prostate cancer cells
2005 - 2008 Novel therapy for muscle invasive bladder cancer using glyco-biological approach
2005 - 2006 New therapy for renal cell carcinoma with down regulation of glycosyltransferase gene
2003 - 2005 The roles of sialyltransferases involved in malignant progression of renal cell carcinoma
2002 - 2004 Glycotherapy for renal cell carcinoma
Show all
Papers (259)：
Taro Akai, Naoki Kawamorita, Tetsuro Shiraiwa, Mahoro Watanabe, Tomonori Sato, Takuma Sato, Emi Yokoyama, Masumi Ishibashi, Zen Watanabe, Akihiro Ito. A severe case of the bladder inversion treated by total cystectomy and hysterectomy with ileal conduit. IJU case reports. 2025. 8. 2. 85-88
Mahoro Watanabe, Naoki Kawamorita, Tetsuro Shiraiwa, Tomonori Sato, Takuma Sato, Yoshihide Kawasaki, Shinichi Yamashita, Akiko Ebata, Satoko Sato, Akihiro Ito. Distant recurrence of non-muscle invasive bladder cancer 8 years after initial treatment. IJU case reports. 2024. 7. 6. 448-453
Takuma Sato, Takeshi Sano, Hisanobu Adachi, Yoshihiro Ikeda, Jun Takemoto, Shingo Myoen, Koji Mitsuzuka, Atsushi Kyan, Hiroshi Aoki, Satoru Tokuyama, et al. Assessment of Clinicopathological Characteristics and Clinical Outcomes of Patients who Developed Non-Muscle-Invasive Bladder Cancer after Radiotherapy for Prostate Cancer: A Retrospective Multicenter Study. The Tohoku journal of experimental medicine. 2024
Prospective randomized phase II trial of single early intravesical instillation of THP for prevention of bladder recurrence after nephroureterectomy for UUT-UC
(AUA annual meeting 2011)
Phase III trial of a single early intravesical instillation of pirarubicin in the prevention of bladder recurrence after nephroureterectomy for upper tract urothelial carcinoma
ITO Akihiro 2014 - 現在
- 1990 Tohoku University Faculty of Medicine School of Medicine
- 1990 Tohoku University Faculty of Medicine
Professional career (1)：
Ph D (Tohoku University)
Work history (1)：
2018/12 - 現在 Tohoku University Graduate School of Medicine Department of Urology Professor
Committee career (2)：
2019/04 - 現在 日本泌尿器科学会 ガイドライン委員会
2017/04 - 現在 日本臨床腫瘍研究グループ 効果安全性評価委員
Association Membership(s) (8)：
アメリカ泌尿器科学会
, 日本ロボット外科学会
, 日本排尿機能学会
, JAPANESE SOCIETY OF ENDOUROLOGY
, THE JAPANESE SOCIETY OF CARBOHYDRATE RESEARCH
, THE JAPANESE CANCER ASSOCIATION
, JAPAN SOCIETY OF CLINICAL ONCOLOGY
, THE JAPANESE UROLOGICAL ASSOCIATION
